KOMBOGLYZE? (saxagliptin and metformin HCl Immediate-Release) Receives Positive CHMP Opinion in the European Union for the Treatment of Type 2 Diabetes

Paris and London (ots/PRNewswire) -

Bristol-Myers Squibb Company and AstraZeneca today announced
that the Marketing Authorisation Application for KOMBOGLYZE(TM)
(saxagliptin and metformin HCl immediate-release fixed dose
combination) received a positive opinion from the Committee for
Medicinal Products for Human Use (CHMP), as an adjunct to diet and
exercise, for the treatment of type 2 diabetes in adults who are not
adequately controlled on metformin or those already being treated
with the combination of saxagliptin and metformin as separate
tablets.

The positive opinion was reached after the CHMP reviewed data
from a Phase 3 clinical program that involved 4,326 patients with
type 2 diabetes, including 2,158 individuals receiving saxagliptin
plus metformin.

KOMBOGLYZE combines saxagliptin (also known as ONGLYZA(TM)), a
DPP-4 inhibitor, and metformin immediate-release (metformin IR), a
biguanide, in one tablet for the treatment of type 2 diabetes.

The CHMP's positive opinion on KOMBOGLYZE will now be reviewed by
the European Commission, which has the authority to approve medicines
for the European Union.

About Type 2 Diabetes

In 2010, diabetes was estimated to affect nearly 56 million
people aged 20-79 in Europe, and the prevalence of diabetes in Europe
is projected to reach nearly 67 million by 2030. Type 2 diabetes
accounts for approximately 90 to 95% of all cases of diagnosed
diabetes in adults. Type 2 diabetes is a chronic, progressive disease
characterized by insulin resistance and/or dysfunction of beta cells
in the pancreas, which decreases insulin sensitivity and secretion,
leading to elevated blood glucose levels. Over time, this sustained
hyperglycaemia contributes to worsening insulin resistance and
further beta cell dysfunction. Significant unmet needs exist as
nearly half of treated patients remain uncontrolled on their current
glucose-lowering regimen.

Bristol-Myers Squibb and AstraZeneca Collaboration

Bristol-Myers Squibb and AstraZeneca entered into a collaboration
in January 2007 to enable the companies to research, develop and
commercialise select investigational drugs for type 2 diabetes. The
Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated
to global patient care, improving patient outcomes and creating a new
vision for the treatment of type 2 diabetes.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical
business with a primary focus on the discovery, development and
commercialisation of prescription medicines for gastrointestinal,
cardiovascular, neuroscience, respiratory and inflammation, oncology
and infectious disease. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding product development. Such forward-looking statements
are based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Among other risks, there can be no guarantee that
Komboglyze will receive regulatory approval or, if approved, that it
will become a commercially successful product. Forward-looking
statements in this press release should be evaluated together with
the many uncertainties that affect Bristol-Myers Squibb's business,
particularly those identified in the cautionary factors discussion in
Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended
December 31, 2010, in our Quarterly Reports on Form 10-Q and our
Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.

AstraZeneca Forward-Looking Statement

The statements contained herein include forward-looking
statements. Although we believe our expectations are based on
reasonable assumptions, any forward-looking statements, by their very
nature, involve risks and uncertainties and may be influenced by
factors that could cause actual outcomes and results to be materially
different from those predicted. The forward-looking statements
reflect knowledge and information available at the date of the
preparation of this press release and the Company undertakes no
obligation to update these forward-looking statements. Important
factors that could cause actual results to differ materially from
those contained in forward-looking statements, certain of which are
beyond our control, include, among other things, those risk factors
identified in the Company's Annual Report and Form 20-F Information
2010. Nothing contained herein should be construed as a profit
forecast.

ots Originaltext: Bristol-Myers Squibb Company and AstraZeneca
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Media: Carmel Hogan, Bristol-Myers Squibb,
+33-6-74-10-76-58, carmel.hogan@bms.com; Kirsten Evraire,
AstraZeneca,
+1-302-885-0435, kirsten.evraire@astrazeneca.com; Investors: John
Elicker,
Bristol-Myers Squibb, +1-609-252-4611, john.elicker@bms.com; Karl
Hard,
AstraZeneca, +44-207-604-8123, karl.j.hard@astrazeneca.com